Business Overview: InfuSystem Holdings, Inc. (NYSE American: INFU)

---

Executive Summary

InfuSystem Holdings, Inc. is a national healthcare services provider that facilitates outpatient care by supplying, servicing, and supporting durable medical equipment (DME) — most notably ambulatory infusion pumps used in oncology — to hospitals, oncology practices, ambulatory surgery centers, and other alternate-site providers. Headquartered in Rochester Hills, Michigan, and originally formed in 2005, the company operates from seven U.S. and Canadian locations and serves patients and providers through a combination of direct equipment supply, billing, nursing support, and biomedical repair services.

Its largest business, oncology infusion-pump services, generated about 87% of Patient Services net revenue in 2025, with the remainder spread across pain management and wound care — a focused but diversifying "last-mile" healthcare-equipment services model.

---

1. Core Business Model & How They Work

InfuSystem operates a two-platform model that sits between DME manufacturers/healthcare providers and the patients who ultimately use the equipment at home or in alternate-site settings.

[ DME manufacturers / healthcare providers ] ➡️ [ InfuSystem equipment, logistics, nursing support, biomedical service ] ➡️ [ Patient (clinic-to-home) ] ➡️ [ Billing of ~840 third-party payer networks ]

Key Operational Drivers

1. Patient Services (lead platform): provides "last-mile," clinic-to-home solutions for complex DME — InfuSystem supplies the equipment and consumables, manages logistics, offers 24/7 nursing support, bills third-party payers directly, and performs biomedical servicing.
2. Device Solutions (secondary platform): offers equipment rental/sale, consumable sales, and biomedical support directly to existing provider customers on a direct-payer basis, rather than billing patients' insurance.
3. Broad payer network: the company bills under pre-negotiated or proprietary fee schedules across nearly 840 third-party payer networks, with no single payer or customer exceeding 10% of net revenue in 2025 or 2024 — meaningfully reducing concentration risk.
4. Acquisitive growth in adjacent care categories: InfuSystem has expanded beyond its oncology core into pain management and wound care via acquisitions (e.g., Apollo Medical Supply's assets, May 2025) and partnerships (e.g., with Sanara MedTech via SI Healthcare Technologies).

---

2. Business Segments

                         ┌───────────────────────────┐
                         │   InfuSystem Holdings       │
                         └─────────────┬───────────────┘
                                       │
                 ┌─────────────────────┴─────────────────────┐
                 ▼                                           ▼
        Patient Services (lead platform)          Device Solutions
   ┌──────────────┬──────────────┬─────────────┐   (rental/sale,
   │  Oncology     │  Pain         │  Wound      │   consumables,
   │  (~87% of     │  Management   │  Care       │   biomedical
   │  segment rev.)│               │             │   service)
   └──────────────┴──────────────┴─────────────┘

• Patient Services – Oncology: electronic ambulatory infusion pumps and disposable kits for continuous chemotherapy infusion, with ~43% of segment revenue from colorectal cancer treatments and ~44% from other disease states.
• Patient Services – Pain management: pumps and services for post-surgical continuous peripheral nerve block, including the proprietary BlockPain Dashboard.
• Patient Services – Wound care: negative pressure wound therapy devices, advanced wound dressings, and (added in 2025) pneumatic compression devices.
• Device Solutions: sale/rental of new and pre-owned pumps, consumable sales, and biomedical recertification/maintenance/repair, expanded through the FilAMed and OB Healthcare acquisitions (2021).

---

3. Product Portfolio

---

4. Competitive Landscape

InfuSystem identifies five distinct competitor groups:

• National DME providers and service companies — scale competitors across multiple geographies.
• Regional DME providers — smaller, geographically focused rivals.
• Hospital-owned DME providers — health systems that keep equipment servicing in-house.
• Physician providers that retain their own pumps — practices that choose not to outsource equipment management.
• Home care infusion providers — companies focused specifically on home infusion therapy.

InfuSystem cites several barriers to entry supporting its position: breadth of its payer network, economies of scale, long-standing oncology provider relationships, a large pump rental fleet, seven-location same/next-day delivery coverage, and in-house field biomedical technicians/repair capability. Notably, the company does not perform R&D on the pumps themselves (which are manufactured by third parties) but invests in information technology and service infrastructure instead.

---

5. Strategic Strengths & Risks

Strengths

• Deep, diversified payer network (~840 payer relationships, no customer/payer over 10% of revenue) substantially reduces concentration risk relative to peers reliant on a handful of large payers.
• Long-standing oncology provider relationships and national logistics footprint create meaningful switching costs and barriers to new entrants.
• Diversification into pain management and wound care (partly via M&A) reduces dependence on a single therapeutic category.
• Asset-heavy but well-utilized rental fleet ($109.1 million historical cost) supports recurring rental and service revenue.

Risks

• Heavy reliance on third-party reimbursement (Medicare, private payers) means policy or reimbursement-rate changes could materially affect revenue and margins.
• Still concentrated in oncology infusion despite diversification efforts — a shift in chemotherapy administration settings or pump technology could disrupt the core business.
• Competes against larger national DME providers with potentially greater scale and resources, as well as hospital systems increasingly keeping DME servicing in-house.
• Growth-by-acquisition strategy (Apollo Medical Supply, FilAMed, OB Healthcare) carries integration risk and could strain capital allocation if execution falters.

---

6. Financial Overview

---

Summary Conclusion

InfuSystem has built a focused but increasingly diversified "last-mile" healthcare-equipment services business around its dominant oncology infusion-pump franchise, reinforced by a broad payer network, national logistics and biomedical-service infrastructure, and recent expansion into pain management and wound care. Its moat is grounded in real operational barriers — payer-network breadth, provider relationships, and service infrastructure that are slow for a regional rival to replicate — rather than any patented technology. The biggest forward risk is reimbursement policy: because the business is fundamentally a pass-through of third-party payer billing for DME, any adverse shift in Medicare or private-payer reimbursement for ambulatory infusion or related DME categories would flow directly through to InfuSystem's revenue and margins.